公开(公告)号：US20180312806A1

公开(公告)日：2018-11-01

申请号：US15823869

申请日：2017-11-28

Applicant: CellScript, LLC

Inventor： Cynthia Chin ,  Anthony D. Person ,  Gary A. Dahl

IPC: C12N5/078 ,  A61K38/16 ,  C07K14/005 ,  C12N5/074 ,  C12N5/077 ,  A61K31/711 ,  A61K38/21 ,  A61K38/17 ,  C07K14/705 ,  A61K31/7105 ,  C07K14/715

CPC classification number: C12N5/0634 ,  A61K31/7105 ,  A61K31/711 ,  A61K38/162 ,  A61K38/1774 ,  A61K38/21 ,  C07K14/005 ,  C07K14/70503 ,  C07K14/7156 ,  C12N5/0658 ,  C12N5/0696 ,  C12N2710/20022 ,  C12N2710/22022 ,  C12N2710/24122 ,  C12N2760/16122 ,  A61K2300/00

Abstract: The present invention provides methods, kits, and compositions for reducing an innate immune system response in a human or animal cell, tissue or organism. One embodiment comprises: introducing an Agent mRNA comprising in vitro-synthesized mRNA encoding one or more proteins that affect the induction, activity or response of an innate immune response pathway; whereby, the innate immune response in the cell, tissue or organism is reduced compared to the innate immune response in the absence of the Agent mRNA. Other embodiments are methods, compositions and kits for using an Agent mRNA for treating a disease or medical condition in a human or animal that exhibits symptoms of an elevated innate immune system, or for reducing an innate immune response that is induced in a human or animal cell, tissue or organism by a Foreign Substance that is administered to the cell, tissue or organism.

公开(公告)号：US20210000926A1

公开(公告)日：2021-01-07

申请号：US16968792

申请日：2019-02-19

Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Servic ,  CELLSCRIPT, LLC

Inventor： Suk See De Ravin ,  Harry L. Malech ,  Ron Meis ,  Gary A. Dahl

IPC: A61K38/44 ,  A61K35/17 ,  A61K35/15 ,  C12N9/02 ,  C12N5/0787 ,  C12N5/0783 ,  A61P31/00 ,  A61K35/28 ,  A61K45/06

Abstract: Provided are compositions and methods for treating a subject having a primary immune deficiency (PID), for example who is suffering from a chronic viral, bacterial, or fungal infection, using autologous granulocytes, autologous lymphocytes, and/or NK cells containing exogenous mRNA encoding the missing or defective protein.

公开(公告)号：US20210079346A1

公开(公告)日：2021-03-18

申请号：US17034999

申请日：2020-09-28

Applicant: CellScript, LLC

Inventor： Cynthia Chin ,  Anthony D. Person ,  Gary A. Dahl

IPC: C12N5/078 ,  A61K38/16 ,  C07K14/705 ,  C07K14/715 ,  C07K14/005 ,  A61K31/7105 ,  A61K38/17 ,  A61K38/21 ,  A61K31/711 ,  C12N5/077 ,  C12N5/074

Abstract: The present invention provides methods, kits, and compositions for reducing an innate immune system response in a human or animal cell, tissue or organism. One embodiment comprises: introducing an Agent mRNA comprising in vitro-synthesized mRNA encoding one or more proteins that affect the induction, activity or response of an innate immune response pathway; whereby, the innate immune response in the cell, tissue or organism is reduced compared to the innate immune response in the absence of the Agent mRNA. Other embodiments are methods, compositions and kits for using an Agent mRNA for treating a disease or medical condition in a human or animal that exhibits symptoms of an elevated innate immune system, or for reducing an innate immune response that is induced in a human or animal cell, tissue or organism by a Foreign Substance that is administered to the cell, tissue or organism.

公开(公告)号：US10793831B2

公开(公告)日：2020-10-06

申请号：US15823869

申请日：2017-11-28

Applicant: CellScript, LLC

Inventor： Cynthia Chin ,  Anthony D. Person ,  Gary A. Dahl

IPC: C12N5/078 ,  A61K38/16 ,  C07K14/705 ,  C07K14/715 ,  C07K14/005 ,  A61K31/7105 ,  A61K38/17 ,  A61K38/21 ,  A61K31/711 ,  C12N5/077 ,  C12N5/074

Abstract: The present invention provides methods, kits, and compositions for reducing an innate immune system response in a human or animal cell, tissue or organism. One embodiment comprises: introducing an Agent mRNA comprising in vitro-synthesized mRNA encoding one or more proteins that affect the induction, activity or response of an innate immune response pathway; whereby, the innate immune response in the cell, tissue or organism is reduced compared to the innate immune response in the absence of the Agent mRNA. Other embodiments are methods, compositions and kits for using an Agent mRNA for treating a disease or medical condition in a human or animal that exhibits symptoms of an elevated innate immune system, or for reducing an innate immune response that is induced in a human or animal cell, tissue or organism by a Foreign Substance that is administered to the cell, tissue or organism.